Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31171203 | 0.94 | DUT (0.40) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL12013275 | 0.94 | DUT (0.40) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL16898660 | 0.94 | DUT (0.40) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10982965 | 0.88 | KDM4E (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10949282 | 0.88 | KDM4E (0.58) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10943473 | 0.86 | TSHR (0.56) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL2152291 | 0.86 | KDM4E (0.40) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10990981 | 0.86 | TSHR (0.56) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL1143263 | 0.86 | TSHR (0.56) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4235404 | 0.86 | TSHR (0.56) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938297-B2 | Process for the synthesis of everolimus and intermediates thereof | Cipia Limited (IN) | 2018-04-10 | — | — | US | disclosed |
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | CIPLA LIMITED (IN) | 2017-08-03 | — | — | US | disclosed |
| CN-101367794-B | Preparation method for quinazoline derivants and medical uses thereof | SHANGHAI HENGRUI PHARM CO LTD | 2013-07-10 | — | — | CN | disclosed |
| EP-1061062-B1 | PROCESS FOR PRODUCING BUTANETRIOL DERIVATIVES | DAISO CO LTD (JP) | 2009-02-18 | — | — | EP | disclosed |
| CN-101367794-A | Preparation method for quinazoline derivants and medical uses thereof | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2009-02-18 | — | — | CN | disclosed |
| US-20040024261-A1 | Process for preparing butanetriol derivative | DAISO CO., LTD. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6620977-B1 | Reacting 1,2,4-butanetriol in multiple steps with specified reagents using selective protection and deprotection of hydroxyl groups | DAISO CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| EP-1061062-A1 | PROCESS FOR PRODUCING BUTANETRIOL DERIVATIVE | DAISO CO., LTD. (JP) | 2000-12-20 | — | — | EP | disclosed |
| EP-0140307-A2 | 7-Oxabicycloheptane ethers | E.R. Squibb & Sons, Inc. (US) | 1985-05-08 | — | — | EP | disclosed |
| US-4513103-A | 7-Oxabicycloheptane ethers useful in the treatment of thrombolytic disease | E. R. SQUIBB & SONS, INC. (US) | 1985-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | MTOR, RICTOR, RPTOR | USP2 4476/4885TSHR 4306/4885KDM4E 975/4885 |
| US-20040024261-A1 | Process for preparing butanetriol derivative | CYP4B1, CYP11B2, CYP11B1 | USP2 1419/4885TSHR 2183/4885KDM4E 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.